

**ABSTRACT OF THE DISCLOSURE**

The present invention describes compounds comprising new and useful peptides and peptidomimetics that can bind to CD23. They are capable of reducing inflammatory responses associated with auto-immune diseases, chronic inflammatory diseases, allergies and other inflammatory conditions such as those mediated by the mammalian immune system. Compounds of the present invention relate to a CD23-binding peptide wherein said peptide comprises an amino-acid sequence of X<sub>1</sub>-X<sub>2</sub>- X<sub>3</sub>-X<sub>4</sub>-X<sub>5</sub>-X<sub>6</sub>-X<sub>7</sub>-X<sub>8</sub>, wherein: X<sub>1</sub> is Phe, or is absent; X<sub>2</sub> is His or Ala; X<sub>3</sub> is Glu, Ser, Ala, Asn, Lys, or Cys; X<sub>4</sub> is Asn, Phe, Gln, Pro, Ser, or Ala; X<sub>5</sub> is Trp; X<sub>6</sub> is Pro, Arg, Glu, Gly, Cys, or Lys; X<sub>7</sub> is Ser, Pro, Leu, Thr Ala, Gly, Asn, or absent; and X<sub>8</sub> is Phe, Gly, or is absent.